Search

Your search keyword '"Laille, A"' showing total 173 results
Start Over Author "Laille, A" Language english
173 results on '"Laille, A"'

1. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

Author

Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K. A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D. R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, and Zwaan, Christian M.

Published
2023
Full Text
View/download PDF

3. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

4. P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Author

Nicolas Boissel, Patrice Chevallier, Kevin Curran, Gary Schiller, Hongtau Liu, Richard Larson, Daniel J. Deangelo, Jean-Baptiste Mear, Stephan Grupp, André Baruchel, Marina Konopleva, Alexandra Lacroce, Caroline Roudet, Ana Korngold, Katie Newhall, Eric Laille, Daniel Lee, Mark Frattini, and Nitin Jain

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. Malthus y Darwin. Ciencia, educación y formas de vida.

Author

Margarita Hernández Laille

Subjects
Malthus, Darwin, evolución, crisis, educación, Aesthetics of cities. City planning and beautifying, NA9000-9428, Anthropology, GN1-890
Abstract

Este trabajo argumenta que Thomas Robert Malthus, con su An essay on the principle of population (Ensayo sobre el principio de la población), publicado en 1798, y Charles R. Darwin, con la publicación en 1859 de On the origin of species by means of natural selection (El origen de las especies mediante la selección natural), nos previnieron de los riesgos que se avecinaban para la supervivencia de las especies, incluida la especie humana, Homo sapiens, y nos enseñaron con sus criterios educativos que la educación era una herramienta indispensable para llevar una forma de vida que nos alejaría del desastre. Desde que Darwin publicó el Origen de las especies, su teoría fue introducida en las aulas inglesas y poco después se fue enseñando en los distintos países. En España, los conceptos darwinistas se incluyeron por primera vez en un libro de texto de ciencias naturales para la segunda enseñanza en el año 1867 y, a partir de entonces, la enseñanza de la teoría de la evolución fue muy heterogénea. Dado que las ideas de Darwin afectan a todos los campos del saber, tanto científicos como sociales y humanísticos, este artículo propone que su enseñanza se presta a ser implementada con una metodología interdisciplinar y en edades tempranas, para que la población pueda adquirir desde los primeros niveles educativos una visión holística y multidisciplinar de la vida.

Published
2023
Full Text
View/download PDF

14. Understanding public administrators' and citizens' preferences for a successful transition to pesticide-free urban green spaces.

Author

Lefebvre, Marianne, Espinosa Goded, Maria, Maslianskaia-Pautrel, Masha, and Laille, Pauline

Subjects
CITIZENS, PUBLIC spaces, PESTICIDES, FRENCH people, BUDGET
Abstract

Bans on the cosmetic use of pesticides in urban green spaces (UGS) is part of the toolbox to reduce pesticide use. While most technical barriers have been lifted, the acceptability of the global changes induced by pesticide-free UGS management is questioned. Public administrators in charge of UGSs have their own preferences and poorly informed opinions on citizens' ones. A Discrete Choice Experiment approach was adopted to investigate the discrepancy between the preferences of French citizens and public administrators in charge of technical and budget decisions, in 2017, when the pesticide ban was enforced. Results indicate that the most important differences are in the willingness to improve the working conditions of the maintenance teams, the interest in more natural UGSs and the relevance of communication on the pesticide ban. By challenging some of the opinions of UGS administrators with regard to citizens' preferences, our results remove some of the barriers to a successful transition toward pesticide-free UGSs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

Author

Rubio-San-Simón, Alba, van Eijkelenburg, Natasha K. A., Hoogendijk, Raoull, Hasle, Henrik, Niemeyer, Charlotte M., Dworzak, Michael N., Zecca, Marco, Lopez-Yurda, Marta, Janssen, Julie M., Huitema, Alwin D. R., van den Heuvel-Eibrink, Marry M., Laille, Eric J., van Tinteren, Harm, and Zwaan, Christian M.

Subjects
AZACITIDINE, CHILD patients, HEMATOPOIETIC stem cell transplantation, CONSORTIA, MYELODYSPLASTIC syndromes
Abstract

Background: Advanced myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematological malignancies in children. A second allograft is recommended if a relapse occurs after hematopoietic stem cell transplantation, but the outcome is poor. Objective: We conducted a phase I/II multicenter study to evaluate the safety, pharmacokinetics, and activity of azacitidine in children with relapsed MDS/JMML prior to the second hematopoietic stem cell transplantation. Methods: Patients enrolled from June 2013 to March 2019 received azacitidine intravenously/subcutaneously once daily on days 1–7 of a 28-day cycle. The MDS and JMML cohorts followed a two-stage design separately, with a safety run-in for JMML. Response and safety data were used to evaluate efficacy and establish the recommended dose. Pharmacokinetics was also analyzed. The study closed prematurely because of low recruitment. Results: Six patients with MDS and four patients with JMML received a median of three and five cycles, respectively. Azacitidine 75 mg/m2 was well tolerated and plasma concentration–time profiles were similar to observed in adults. The most prevalent grade 3–4 adverse event was myelotoxicity. No responses were seen in patients with MDS, but 83% achieved stable disease; four patients underwent an allotransplant. Overall response rate in the JMML cohort was 75% (two complete responses; one partial response) and all responders underwent hematopoietic stem cell transplantation. One-year overall survival was 67% (95% confidence interval 38–100) in MDS and 50% (95% confidence interval 19–100) in JMML. Conclusions: Azacitidine 75 mg/m2 prior to a second hematopoietic stem cell transplantation is safe in children with relapsed MDS/JMML. Although the long-term advantage remains to be assessed, this study suggests that azacitidine is an efficacious option for relapsed JMML. Clinical Trial Registration: EudraCT 2010-022235-10. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Population Pharmacokinetics of Oral Azacitidine, and Exposure–Response Analysis in Acute Myeloid Leukemia.

Author

Gaudy, Allison, Laille, Eric, Bailey, Rochelle, Zhou, Simon, Skikne, Barry, and Beach, C.L.

Subjects
AZACITIDINE, ACUTE myeloid leukemia, HEMATOPOIETIC stem cell transplantation, MYELODYSPLASTIC syndromes, CHRONIC leukemia, PHARMACOKINETICS, CHILD patients
Abstract

Oral azacitidine (oral‐AZA) maintenance is approved for adults with acute myeloid leukemia (AML) in remission post‐intensive chemotherapy, not proceeding to hematopoietic stem cell transplantation. This study aimed to develop a population pharmacokinetic (PopPK) model to characterize oral‐AZA concentration–time profiles in patients with AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia. PopPK‐estimated exposure parameters were used to evaluate exposure–response relationships in the phase III QUAZAR AML‐001 study. The PopPK dataset comprised 286 patients with 1,933 evaluable oral‐AZA concentration records. The final PopPK model was a one‐compartment model with first‐order absorption incorporating an absorption lag time and first‐order elimination. Regression analyses identified two oral‐AZA exposure parameters (area under the plasma concentration–time curve at steady state (AUCss); maximum plasma concentration (Cmax)) as statistically significant predictors for relapse‐free survival (hazard ratio (HR) = 0.521, P < 0.001; HR = 0.630, P = 0.013; respectively), and AUCss as a significant predictor for overall survival (HR = 0.673, P = 0.042). The probability of grade ≥ 3 neutropenia was significantly increased with increases in AUCss (odds ratio (OR) = 5.71, 95% confidence interval (CI) = 2.73–12.62, P < 0.001), cumulative AUC through cycles 1 to 6 (OR = 2.71, 95% CI = 1.76–4.44, P < 0.001), and Cmax at steady‐state (OR = 2.38, 95% CI = 1.23–4.76, P = 0.012). A decreasing trend was identified between AUCss and relapse‐related schedule extensions, vs. an increasing trend between AUCss and event‐related dose reductions. As the majority (56.8%) of patients required no dose modifications, and the proportions requiring schedule extension (19.4%) or dose reduction (22.9%) were almost equal, oral‐AZA 300 mg once daily for 14 days is the optimal dosing schedule balancing survival benefit and safety risk. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study

Author

Maruyama, Dai, Tobinai, Kensei, Ogura, Michinori, Uchida, Toshiki, Hatake, Kiyohiko, Taniwaki, Masafumi, Ando, Kiyoshi, Tsukasaki, Kunihiro, Ishida, Takashi, Kobayashi, Naoki, Ishizawa, Kenichi, Tatsumi, Yoichi, Kato, Koji, Kiguchi, Toru, Ikezoe, Takayuki, Laille, Eric, Ro, Tokihiro, Tamakoshi, Hiromi, Sakurai, Sanae, and Ohtsu, Tomoko

Published
2017
Full Text
View/download PDF

19. Variable Very-High-Energy Gamma-Ray Emission from the Microquasar LS I +61 303

Author

Albert, J., Aliu, E., Anderhub, H., Antoranz, P., Armada, A., Asensio, M., Baixeras, C., Barrio, J. A., Bartelt, M., Bartko, H., Bastieri, D., Bavikadi, S. R., Bednarek, W., Berger, K., Bigongiari, C., Biland, A., Bisesi, E., Bock, R. K., Bordas, P., Bosch-Ramon, V., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Chilingarian, A., Ciprini, S., Coarasa, J. A., Commkhau, S., Contreras, J. L., Cortina, J., Curtef, V., Danielyan, V., Dazzi, F., De Angelis, A., de los Reyes, R., De Lotto, B., Domingo-Santamaria, E., Dorner, D., Doro, M., Errando, M., Fagiolini, M., Ferenc, D., Fernandez, E., Firpo, R., Flix, J., Fonseca, M. V., Font, L., Fuchs, M., Galante, N., Garczarczyk, M., Gaug, M., Giller, M., Goebel, F., Hakobyan, D., Hayashida, M., Hengstebeck, T., Höhne, D., Hose, J., Hsu, C. C., Isar, P. G., Jacon, P., Kalekin, O., Kosyra, R., Kranich, D., Laatiaoui, M., Laille, A., Lenisa, T., Liebing, P., Lindfors, E., Lombardi, S., Longo, F., Lopez, J., López, M., Lorenz, E., Lucarelli, F., Majumdar, P., Maneva, G., Mannheim, K., Mansutti, O., Mariotti, M., Martínez, M., Mase, K., Mazin, D., Merck, C., Meucci, M., Meyer, M., Miranda, J. M., Mirzoyan, R., Mizobuchi, S., Moralejo, A., Nilsson, K., Oña-Wilhelmi, E., Orduña, R., Otte, N., Oya, I., Paneque, D., Paoletti, R., Paredes, J. M., Pasanen, M., Pascoli, D., Pauss, F., Pavel, N., Pegna, R., Persic, M., Peruzzo, L., Piccioli, A., Poller, M., Pooley, G., Prandini, E., Raymers, A., Rhode, W., Ribó, M., Rico, J., Riegel, B., Rissi, M., Robert, A., Romero, G. E., Rügamer, S., Saggion, A., Sánchez, A., Sartori, P., Scalzotto, V., Scapin, V., Schmitt, R., Schweizer, T., Shayduk, M., Shinozaki, K., Shore, S. N., Sidro, N., Sillanpää, A., Sobczynska, D., Stamerra, A., Stark, L. S., Takalo, L., Temnikov, P., Tescaro, D., Teshima, M., Tonello, N., Torres, A., Torres, D. F., Turini, N., Vankov, H., Vitale, V., Wagner, R. M., Wibig, T., Wittek, W., Zanin, R., and Zapatero, J.

Published
2006

20. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Author

Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo, Institut Català de la Salut, [de Botton S] Gustave Roussy, Université Paris-Saclay, Villejeuf, France. [Montesinos P] Hospital Universitari i Politecnic La Fe, Valencia, Spain. [Schuh AC] Princess Margaret Cancer Centre, Toronto, ON, Canada. [Papayannidis C] IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy. [Vyas P] Oxford Biomedical Research Centre and Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom. [Wei AH] The Alfred Hospital, Melbourne, VIC, Australia. Monash University, Melbourne, VIC, Australia. [Salamero O] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Otros calificadores::/uso terapéutico [Otros calificadores], Immunology, Genetic Phenomena::Genetic Variation::Mutation [PHENOMENA AND PROCESSES], Medicaments antineoplàstics - Ús terapèutic, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Cell Biology, Hematology, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Biochemistry, neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES], Anomalies cromosòmiques, Leucèmia mieloide aguda - Aspectes genètics, Leucèmia mieloide aguda - Tractament, Other subheadings::/therapeutic use [Other subheadings], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS]
Abstract

Enasidenib; Conventional care Enasidenib; Atenció convencional Enasidenib; Atención convencional This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies. Patients were first preselected to a CCR (azacitidine, intermediate-dose cytarabine, low-dose cytarabine, or supportive care) and then randomized (1:1) to enasidenib 100 mg per day or CCR. The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), time to treatment failure (TTF), overall response rate (ORR), hematologic improvement (HI), and transfusion independence (TI). Overall, 319 patients were randomized to enasidenib (n = 158) or CCR (n = 161). The median age was 71 years, median (range) enasidenib exposure was 142 days (3 to 1270), and CCR was 36 days (1 to 1166). One enasidenib (0.6%) and 20 CCR (12%) patients received no randomized treatment, and 30% and 43%, respectively, received subsequent AML-directed therapies during follow-up. The median OS with enasidenib vs CCR was 6.5 vs 6.2 months (HR [hazard ratio], 0.86; P = .23); 1-year survival was 37.5% vs 26.1%. Enasidenib meaningfully improved EFS (median, 4.9 vs 2.6 months with CCR; HR, 0.68; P = .008), TTF (median, 4.9 vs 1.9 months; HR, 0.53; P < .001), ORR (40.5% vs 9.9%; P

Published
2022

24. A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AML)

Author

CRISTINA PAPAYANNIDIS, Dinardo, C., Montesinos, P., Schuh, A., Vyas, P., Wei, A., Ommen, H., Semochkin, S., Kim, H., Larson, R., Koprivnikar, J., Frankfurt, O., Thol, F., Chromik, J., Byrne, J., Pigneux, A., Thomas, X., Salamero, O., Vidriales, M., Doronin, V., Dohner, H., Fathi, A., Laille, E., Yu, X., Hasan, M., Martin-Regueira, P., and Botton, S.

Published
2021
Full Text
View/download PDF

26. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Author

Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R Cogle, Steven D Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, and Kyle J MacBeth

Subjects
Medicine, Science
Abstract

CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well tolerated, and reduced DNA methylation. Extending dosing of CC-486 beyond 7 days would increase duration of azacitidine exposure. We hypothesized that extended dosing would therefore provide more sustained epigenetic activity. Reported here are the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of CC-486 extended dosing schedules in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) from part 2 of this study. PK and/or PD data were available for 59 patients who were sequentially assigned to 1 of 4 extended CC-486 dosing schedules: 300mg once-daily or 200mg twice-daily for 14 or 21 days per 28-day cycle. Both 300mg once-daily schedules and the 200mg twice-daily 21-day schedule significantly (all P < .05) reduced global DNA methylation in whole blood at all measured time points (days 15, 22, and 28 of the treatment cycle), with sustained hypomethylation at cycle end compared with baseline. CC-486 exposures and reduced DNA methylation were significantly correlated. Patients who had a hematologic response had significantly greater methylation reductions than non-responding patients. These data demonstrate that extended dosing of CC-486 sustains epigenetic effects through the treatment cycle.ClinicalTrials.gov NCT00528983.

Published
2015
Full Text
View/download PDF

28. Improving the performance of the single-dish Cherenkov telescope MAGIC through the use of signal timing

Author

Aliu, E., Anderhub, H., Antonelli, L.A., Antoranz, P., Backes, M., Baixeras, C., Barrio, J.A., Bartko, H., Bastieri, D., Becker, J.K., Bednarek, W., Berger, K., Bernardini, E., Biland, A., Bock, R.K., Bonnoli, G., Bordas, P., Borla Tridon, D., Bosch-Ramon, V., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Chilingarian, A., Commichau, S., Contreras, J.L., Cortina, J., Costado, M.T., Covino, S., Curtef, V., Dazzi, F., De Angelis, A., De Cea del Pozo, E., de los Reyes, R., De Lotto, B., De Maria, M., De Sabata, F., Delgado Mendez, C., Dominguez, A., Dorner, D., Doro, M., Elsässer, D., Errando, M., Fagiolini, M., Ferenc, D., Fernández, E., Firpo, R., Fonseca, M.V., Font, L., Galante, N., García López, R.J., Garczarczyk, M., Gaug, M., Goebel, F., Hadasch, D., Hayashida, M., Herrero, A., Höhne, D., Hose, J., Hsu, C.C., Huber, S., Jogler, T., Kranich, D., La Barbera, A., Laille, A., Leonardo, E., Lindfors, E., Lombardi, S., Longo, F., López, M., Lorenz, E., Majumdar, P., Maneva, G., Mankuzhiyil, N., Mannheim, K., Maraschi, L., Mariotti, M., Martínez, M., Mazin, D., Meucci, M., Meyer, M., Miranda, J.M., Mirzoyan, R., Moles, M., Moralejo, A., Nieto, D., Nilsson, K., Ninkovic, J., Otte, N., Oya, I., Paoletti, R., Paredes, J.M., Pasanen, M., Pascoli, D., Pauss, F., Pegna, R.G., Perez-Torres, M.A., Persic, M., Peruzzo, L., Piccioli, A., Prada, F., Prandini, E., Puchades, N., Raymers, A., Rhode, W., Ribó, M., Rico, J., Rissi, M., Robert, A., Rügamer, S., Saggion, A., Saito, T.Y., Salvati, M., Sanchez-Conde, M., Sartori, P., Satalecka, K., Scalzotto, V., Scapin, V., Schweizer, T., Shayduk, M., Shinozaki, K., Shore, S.N., Sidro, N., Sierpowska-Bartosik, A., Sillanpää, A., Sitarek, J., Sobczynska, D., Spanier, F., Stamerra, A., Stark, L.S., Takalo, L., Tavecchio, F., Temnikov, P., Tescaro, D., Teshima, M., Tluczykont, M., Torres, D.F., Turini, N., Vankov, H., Venturini, A., Vitale, V., Wagner, R.M., Wittek, W., Zabalza, V., Zandanel, F., Zanin, R., and Zapatero, J.

Published
2009
Full Text
View/download PDF

29. Application of the NBS impact evaluation framework: NBS performance and impact evaluation case studies

Author

Dubovik, M., Dumitru, A., Wendling, L., Briega, P., Capobianco, V., Connop, S., Crespo, L., Fermoso, J., Giannico, V., Gómez, S., González, M., Kakoulaki, G., Kumar, P., Leppänen, S., Marijuan, R., Pablo, S., Pérez, J.A., Pilla, F., Rinta-Hiiro, V., Riquelme, H., Sánchez, E., Sánchez, I., Sánchez, J.C., Sánchez, R., San José, E., Sanz, J.M., Sanz, N., Serramia, J., Spano, G., Särkilahti, M., Tomé-Lourido, D., van de Sijpe, K., Verdugo, F., Villazán, A., Vos, P., Zulian, G., Allaert, K., Almenar, J.B., Arnbjerg-Nielsen, K., Baldacchini, C., Basco, L., Beaujouan, V., Benoit, G., Bockarjova, M., Bonelli, S., Bouzouidja, R., Butlin, T., Calatrava, J., Calfapietra, C., Cannavo, P., Caroppi, G., Chancibault, K., Cioffi, M., Dadvand, P., de Bellis, Y., de Keijzer, C., de la Hera, A., Decker, S., Djordjevic, S., Dushkova, D., Faneca, M., Fatima, Z., Ferracini, C., Fleury, G., García, I., García-Alcaraz, M., Gerundo, C., Gil-Roldán, E., Giordano, R., Giugni, M., Gonzalez-Ollauri, A., Guidolotti, G., Haase, D., Heredida, J., Hermawan, T., Herranz-Pascual, K., Hölscher, K., Jermakka, J., Kiss, M., Kraus, F., Körmöndi, B., Laikari, A., Laille, P., Lemée, C., Llorente, M., Lodder, M., Lourido, D.T., Macsinga, I., Manzano, M., Martelli, F., Martins, R., Mayor, B., McKnight, U., Mendizabal, M., Mendonça, R., Mickovski, S.B., Nash, C., Nadim, F., Nolan, P., Oen, A., Olsson, P., Olver, C., Paradiso, F., Petucco, C., Pisani, N., Piton, G., Pugliese, F., Rasmussen, M., Munro, K., Reich, E., Reichborn-Kjennerud, K., Renaud, F., Rhodes, M.L., Robles, V., Rodriguez, F., Roebeling, P., Ruangpan, L., Rugani, B., Rödl, A., Sánchez Torres, A., Sanesi, G., Scharf, B., Silvestri, F., Skodra, J., Stanganelli, M., Szkordilisz, F., Tacnet, J.-M., Vay, L., Vella, S., Vercelli, M., Vojinovic, Z., Werner, A., Wheeler, B., Young, C., Zoritaz, S., zu-Castell Rüdenhausen, M., Dumitru, Adina, and Wendling, Laura

Abstract

No abstract available.

Published
2021

30. Indicators of NBS performance and impact

Author

Wendling, L., Dumitru, A., Arnbjerg-Nielsen, K., Baldacchini, C., Connop, S., Dubovik, M., Fermoso, J., Hölscher, K., Nadim, F., Pilla, F., Renaud, F., Rhodes, M.L., San José, E., Sánchez, R., Skodra, J., Tacnet, J.-M., Zulian, G., Allaert, K., Almassy, D., Ascenso, A., Babí Almenar, J., Basco, L., Beaujouan, V., Benoit, G., Bockarjova, M., Bode, N., Bonelli, S., Bouzouidja, R., Butlin, T., Calatrava, J., Calfapietra, C., Cannavo, P., Capobianco, V., Caroppi, G., Ceccherini, G., Chancibault, K., Cioffi, M., Coelho, S., Dadvand, P., de Bellis, Y., de Keijzer, C., de la Hera, A., De Vreese, R., Decker, S., Djordjevic, S., Dowling, C., Dushkova, D., Eiter, S., Faneca, M., Fatima, Z., Ferracini, C., Fjellstad, W., Fleury, G, Freyer, B., García, I., García-Alcaraz, M., Gerundo, C., Gil-Roldán, E., Giordano, R., Giugni, M., Goličnik Marušić, B., Gómez, S., González, M., Gonzalez-Ollauri, A., Guidolotti, G., Haase, D., Heredida, J., Hermawan, T., Herranz-Pascual, K., Jermakka, J., Jones, L., Kiss, M., Kraus, F., Körmöndi, B., Laikari, A., Laille, P., Lemée, C., Llorente, M., Lodder, M., Macsinga, I., Maes, J., Maia, S., Manderscheid, M., Manzano, M., Martelli, F., Martins, R., Mayor, B., McKnight, U., Mendizabal, M., Mendonça, R., Mickovski, S.B., Miranda, A.I., Moniz, G.C., Munro, K., Nash, C., Nolan, P., Oen, A., Olsson, P., Olver, C., Ozturk, E.D., Paradiso, F., Petucco, C., Pisani, N., Piton, G., Pugliese, F., Rasmussen, M., Ravknikar, Ž., Reich, E., Reichborn-Kjennerud, K., Rinta-Hiiro, V., Robles, V., Rodriguez, F., Roebeling, P., Ruangpan, L, Rugani, B, Rödl, A, Sánchez, I, Sánchez Torres, A, Sanesi, G, Sanz, J.M., Scharf, B., Silvestri, F., Spano, G., Stanganelli, M., Szkordilisz, F., Tomé-Lourido, D., Vay, L., Vela, S., Vercelli, M., Villazán, A., Vojinovic, Z., Werner, A., Wheeler, B., Young, C., Zorita, S., Zandersen, M., zu-Castell Rüdenhausen, M., Dumitru, Adina, and Wendling, Laura

Abstract

No abstract available.

Published
2021

31. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

Author

Paresh Vyas, Dietger Niederwieser, Rena Buckstein, David Valcárcel, Valentina Giai, Gianluigi Reda, C.L. Beach, Guillermo Garcia-Manero, Ignazia La Torre, Jake Shortt, Valeria Santini, Barry S. Skikne, Moshe Mittelman, Lewis R. Silverman, Uwe Platzbecker, Jianhua Zhong, Anna Jonasova, Aristoteles Giagounidis, Luana Fianchi, Maria Diez Campelo, Pierre Fenaux, Stephen Larsen, Esther Oliva, Eric Laille, Antonio Almeida, Francesco Buccisano, Jose F Falantes, and Daniel Menezes

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Anemia, Azacitidine, Placebo-controlled study, Administration, Oral, Lower risk, Oral Azacitidine, Internal medicine, medicine, Humans, Prospective Studies, Prospective cohort study, Survival rate, Aged, Aged, 80 and over, business.industry, Myelodysplastic syndromes, Middle Aged, medicine.disease, Prognosis, Settore MED/15, Survival Rate, Oncology, Myelodysplastic Syndromes, Female, Follow-Up Studies, business, medicine.drug
Abstract

PURPOSE Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion–dependent anemia and thrombocytopenia. METHODS Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI). RESULTS Two hundred sixteen patients received CC-486 (n = 107) or placebo (n = 109). The median age was 74 years, median platelet count was 25 × 109/L, and absolute neutrophil count was 1.3 × 109/L. In the CC-486 and placebo arms, 31% and 11% of patients, respectively, achieved RBC-TI ( P = .0002), with median durations of 11.1 and 5.0 months. Reductions of ≥ 4 RBC units were attained by 42.1% and 30.6% of patients, respectively, with median durations of 10.0 and 2.3 months, and more CC-486 patients had ≥ 1.5 g/dL hemoglobin increases from baseline (23.4% v 4.6%). Platelet hematologic improvement rate was higher with CC-486 (24.3% v 6.5%). Underpowered interim overall survival analysis showed no difference between CC-486 and placebo (median, 17.3 v 16.2 months; P = .96). Low-grade GI events were the most common adverse events in both arms. In the CC-486 and placebo arms, 90% and 73% of patients experienced a grade 3-4 adverse event. Overall death rate was similar between arms, but there was an imbalance in deaths during the first 56 days (CC-486, n = 16; placebo, n = 6), most related to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was 0.57 × 109/L. CONCLUSION CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. More early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.

Published
2021

32. Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., and Boissel, Nicolas

Published
2023
Full Text
View/download PDF

34. FADC signal reconstruction for the MAGIC telescope

Author

Albert, J., Aliu, E., Anderhub, H., Antoranz, P., Armada, A., Asensio, M., Baixeras, C., Barrio, J.A., Bartko, H., Bastieri, D., Becker, J., Bednarek, W., Berger, K., Bigongiari, C., Biland, A., Bock, R.K., Bordas, P., Bosch-Ramon, V., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Chilingarian, A., Ciprini, S., Coarasa, J.A., Commichau, S., Contreras, J.L., Cortina, J., Costado, M.T., Curtef, V., Danielyan, V., Dazzi, F., De Angelis, A., Delgado, C., de los Reyes, R., De Lotto, B., Domingo-Santamaría, E., Dorner, D., Doro, M., Errando, M., Fagiolini, M., Ferenc, D., Fernández, E., Firpo, R., Flix, J., Fonseca, M.V., Font, L., Fuchs, M., Galante, N., García-López, R.J., Garczarczyk, M., Gaug, M., Giller, M., Goebel, F., Hakobyan, D., Hayashida, M., Hengstebeck, T., Herrero, A., Höhne, D., Hose, J., Hsu, C.C., Jacon, P., Jogler, T., Kosyra, R., Kranich, D., Kritzer, R., Laille, A., Lindfors, E., Lombardi, S., Longo, F., López, J., López, M., Lorenz, E., Majumdar, P., Maneva, G., Mannheim, K., Mansutti, O., Mariotti, M., Martínez, M., Mazin, D., Merck, C., Meucci, M., Meyer, M., Miranda, J.M, Mirzoyan, R., Mizobuchi, S., Moralejo, A., Nieto, D., Nilsson, K., Ninkovic, J., Oña-Wilhelmi, E., Otte, N., Oya, I., Panniello, M., Paoletti, R., Paredes, J.M., Pasanen, M., Pascoli, D., Pauss, F., Pegna, R., Persic, M., Peruzzo, L., Piccioli, A., Puchades, N., Prandini, E., Raymers, A., Rhode, W., Ribó, M., Rico, J., Rissi, M., Robert, A., Rügamer, S., Saggion, A., Saito, T., Sánchez, A., Sartori, P., Scalzotto, V., Scapin, V., Schmitt, R., Schweizer, T., Shayduk, M., Shinozaki, K., Shore, S.N., Sidro, N., Sillanpää, A., Sobczynska, D., Stamerra, A., Stark, L.S., Takalo, L., Temnikov, P., Tescaro, D., Teshima, M., Torres, D.F., Turini, N., Vankov, H., Vitale, V., Wagner, R.M., Wibig, T., Wittek, W., Zandanel, F., Zanin, R., and Zapatero, J.

Published
2008
Full Text
View/download PDF

35. Implementation of the Random Forest method for the Imaging Atmospheric Cherenkov Telescope MAGIC

Author

Albert, J., Aliu, E., Anderhub, H., Antoranz, P., Armada, A., Asensio, M., Baixeras, C., Barrio, J.A., Bartko, H., Bastieri, D., Becker, J., Bednarek, W., Berger, K., Bigongiari, C., Biland, A., Bock, R.K., Bordas, P., Bosch-Ramon, V., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Chilingarian, A., Ciprini, S., Coarasa, J.A., Commichau, S., Contreras, J.L., Cortina, J., Costado, M.T., Curtef, V., Danielyan, V., Dazzi, F., De Angelis, A., Delgado, C., de los Reyes, R., De Lotto, B., Domingo-Santamaría, E., Dorner, D., Doro, M., Errando, M., Fagiolini, M., Ferenc, D., Fernández, E., Firpo, R., Flix, J., Fonseca, M.V., Font, L., Fuchs, M., Galante, N., García-López, R.J., Garczarczyk, M., Gaug, M., Giller, M., Goebel, F., Hakobyan, D., Hayashida, M., Hengstebeck, T., Herrero, A., Höhne, D., Hose, J., Huber, S., Hsu, C.C., Jacon, P., Jogler, T., Kosyra, R., Kranich, D., Kritzer, R., Laille, A., Lindfors, E., Lombardi, S., Longo, F., López, J., López, M., Lorenz, E., Majumdar, P., Maneva, G., Mannheim, K., Mariotti, M., Martínez, M., Mazin, D., Merck, C., Meucci, M., Meyer, M., Miranda, J.M., Mirzoyan, R., Mizobuchi, S., Moralejo, A., Nieto, D., Nilsson, K., Ninkovic, J., Oña-Wilhelmi, E., Otte, N., Oya, I., Panniello, M., Paoletti, R., Paredes, J.M., Pasanen, M., Pascoli, D., Pauss, F., Pegna, R., Persic, M., Peruzzo, L., Piccioli, A., Puchades, N., Prandini, E., Raymers, A., Rhode, W., Ribó, M., Rico, J., Rissi, M., Robert, A., Rügamer, S., Saggion, A., Saito, T.Y., Sánchez, A., Sartori, P., Scalzotto, V., Scapin, V., Schmitt, R., Schweizer, T., Shayduk, M., Shinozaki, K., Shore, S.N., Sidro, N., Sillanpää, A., Sobczynska, D., Spanier, F., Stamerra, A., Stark, L.S., Takalo, L., Temnikov, P., Tescaro, D., Teshima, M., Torres, D.F., Turini, N., Vankov, H., Venturini, A., Vitale, V., Wagner, R.M., Wibig, T., Wittek, W., Zandanel, F., Zanin, R., and Zapatero, J.

Published
2008
Full Text
View/download PDF

39. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Author

Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, and Michelle A. Rudek

Subjects
0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Multiple Organ Failure, Phases of clinical research, Antineoplastic Agents, Lymphoma, T-Cell, Article, Romidepsin, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Internal medicine, Depsipeptides, Medicine, Humans, Dosing, Adverse effect, Aged, business.industry, Liver Diseases, Organ dysfunction, Cancer, Middle Aged, medicine.disease, National Cancer Institute (U.S.), United States, 030104 developmental biology, Liver, 030220 oncology & carcinogenesis, Cohort, Female, medicine.symptom, business, medicine.drug
Abstract

Purpose: Romidepsin dosing recommendations for patients with malignancy and varying degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell lymphoma. We conducted a multicenter phase I clinical trial (ETCTN-9008) via the NCI Organ Dysfunction Working Group to investigate safety, first cycle MTD, and pharmacokinetic profile of romidepsin in this setting. Patients and Methods: Patients with select advanced solid tumors or hematologic malignancies were stratified according to hepatic function. Romidepsin was administered intravenously on days 1, 8, and 15 of a 28-day cycle and escalation followed a 3 + 3 design in moderate and severe impairment cohorts. Blood samples for detailed pharmacokinetic analyses were collected after the first dose. Results: Thirty-one patients received one dose of romidepsin and were evaluable for pharmacokinetic analyses in normal (n = 12), mild (n = 8), moderate (n = 5), and severe (n = 6) cohorts. Adverse events across cohorts were similar, and dose-limiting toxicity occurred in two patients (mild and severe impairment cohorts). The MTD was not determined because the geometric mean AUC values of romidepsin in moderate (7 mg/m2) and severe (5 mg/m2) impairment cohort were 114% and 116% of the normal cohort (14 mg/m2). Conclusions: Data from the ETCTN-9008 trial led to changes in the romidepsin labeling to reflect starting dose adjustment for patients with cancer and moderate and severe hepatic impairment, with no adjustment for mild hepatic impairment.

Published
2020

40. Individual preferences regarding pesticide-free management of green-spaces: a discret choice experiment with French citizens

Author

Laille, Pauline, Lefebvre, Marianne, Maslianskaia-Pautrel, Masha, Association Plante et Cité (Plante et Cité), Groupe de Recherche Angevin en Economie et Management (GRANEM), Université d'Angers (UA)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de l'Horticulture et du Paysage, and Université d'Angers (UA)-AGROCAMPUS OUEST-Institut National de l'Horticulture et du Paysage

Subjects
Discrete choice experiment, JEL: Q - Agricultural and Natural Resource Economics • Environmental and Ecological Economics/Q.Q2 - Renewable Resources and Conservation/Q.Q2.Q24 - Land, France, Pesticides, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Individual preferences, JEL: Q - Agricultural and Natural Resource Economics • Environmental and Ecological Economics/Q.Q2 - Renewable Resources and Conservation/Q.Q2.Q26 - Recreational Aspects of Natural Resources, Urban green spaces, JEL: C - Mathematical and Quantitative Methods/C.C2 - Single Equation Models • Single Variables/C.C2.C25 - Discrete Regression and Qualitative Choice Models • Discrete Regressors • Proportions • Probabilities
Published
2020

41. Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

Author

Michael R. Savona, Hani M. Babiker, Dale R. Shepard, Barry S. Skikne, Maen Abdelrahim, Kao Tai Tsai, Joseph Aisner, C.L. Beach, Thai H. Ho, Mohammed M. Milhem, William Jeffery Edenfield, Eric Laille, and Swaminathan P. Iyer

Subjects
Pharmacology, Cancer Research, FOOD EFFECT, Cancer chemotherapy, Adult patients, business.industry, Cancer, Correction, Bioequivalence, Toxicology, medicine.disease, Oral Azacitidine, Bioavailability, Oncology, medicine, Pharmacology (medical), business
Abstract

CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize clinical activity. CC-486 300 mg daily, administered for 14 or 21 days of 28-day treatment cycles, is currently under investigation in two ongoing phase III trials. The 300-mg daily dose in these studies is administered as two 150-mg tablets (Formulation A).We evaluated the bioequivalence of one 300-mg CC-486 tablet (Formulation B) with Formulation A and food effect on Formulation B, in adult patients with cancer in a 2-stage crossover design study.The ratios of the geometric means of the maximum azacitidine plasma concentration (CThe single 300-mg CC-486 tablet was bioequivalent to two 150-mg tablets, which have shown to be efficacious and generally well-tolerated in clinical trials, and can be taken with or without food.

Published
2020

42. Unfolding of differential energy spectra in the MAGIC experiment

Author

Albert, J., Aliu, E., Anderhub, H., Antoranz, P., Armada, A., Asensio, M., Baixeras, C., Barrio, J.A., Bartko, H., Bastieri, D., Becker, J., Bednarek, W., Berger, K., Bigongiari, C., Biland, A., Bock, R.K., Bordas, P., Bosch-Ramon, V., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Chilingarian, A., Ciprini, S., Coarasa, J.A., Commichau, S., Contreras, J.L., Cortina, J., Costado, M.T., Curtef, V., Danielyan, V., Dazzi, F., De Angelis, A., Delgado, C., de los Reyes, R., De Lotto, B., Domingo-Santamaría, E., Dorner, D., Doro, M., Errando, M., Fagiolini, M., Ferenc, D., Fernández, E., Firpo, R., Flix, J., Fonseca, M.V., Font, L., Fuchs, M., Galante, N., García-López, R.J., Garczarczyk, M., Gaug, M., Giller, M., Goebel, F., Hakobyan, D., Hayashida, M., Hengstebeck, T., Herrero, A., Höhne, D., Hose, J., Hsu, C.C., Jacon, P., Jogler, T., Kosyra, R., Kranich, D., Kritzer, R., Laille, A., Lindfors, E., Lombardi, S., Longo, F., López, J., López, M., Lorenz, E., Majumdar, P., Maneva, G., Mannheim, K., Mansutti, O., Mariotti, M., Martínez, M., Mazin, D., Merck, C., Meucci, M., Meyer, M., Miranda, J.M., Mirzoyan, R., Mizobuchi, S., Moralejo, A., Nieto, D., Nilsson, K., Ninkovic, J., Oña-Wilhelmi, E., Otte, N., Oya, I., Panniello, M., Paoletti, R., Paredes, J.M., Pasanen, M., Pascoli, D., Pauss, F., Pegna, R., Persic, M., Peruzzo, L., Piccioli, A., Puchades, N., Prandini, E., Raymers, A., Rhode, W., Ribó, M., Rico, J., Rissi, M., Robert, A., Rügamer, S., Saggion, A., Saito, T., Sánchez, A., Sartori, P., Scalzotto, V., Scapin, V., Schmitt, R., Schweizer, T., Shayduk, M., Shinozaki, K., Shore, S.N., Sidro, N., Sillanpää, A., Sobczynska, D., Stamerra, A., Stark, L.S., Takalo, L., Temnikov, P., Tescaro, D., Teshima, M., Torres, D.F., Turini, N., Vankov, H., Vitale, V., Wagner, R.M., Wibig, T., Wittek, W., Zandanel, F., Zanin, R., and Zapatero, J.

Published
2007
Full Text
View/download PDF

47. Radio Imaging of the Very-High-Energy γ-Ray Emission Region in the Central Engine of a Radio Galaxy

Author

Acciari, V. A., Aliu, E., Arlen, T., Bautista, M., Beilicke, M., Benbow, W., Bradbury, S. M., Buckley, J. H., Bugaev, V., Butt, Y., Byrum, K., Cannon, A., Celik, O., Cesarini, A., Chow, Y. C., Ciupik, L., Cogan, P., Cui, W., Dickherber, R., Fegan, S. J., Finley, J. P., Fortin, P., Fortson, L, Furniss, A., Gall, D., Gillanders, G. H., Grube, J., Guenette, R., Gyuk, G., Hanna, D., Holder, J., Horan, D., Hui, C. M., Humensky, T. B., Imran, A., Kaaret, P., Karlsson, N., Kieda, D., Kildea, J., Konopelko, A., Krawczynski, H., Krennrich, F., Lang, M. J., LeBohec, S., Maier, G., McCann, A., McCutcheon, M., Millis, J., Moriarty, P., Ong, R. A., Otte, A. N., Pandel, D., Perkins, J. S., Petry, D., Pohl, M., Quinn, J., Ragan, K., Reyes, L C., Reynolds, P. T., Roache, E., Rose, H. J., Schroedter, M., Sembroski, G. H., Smith, A W., Swordy, S. P., Theiling, M., Toner, J. A, Vartotta, A., Vincent, S., Wakely, S. P., Ward, J. E., Weekes, T. C., Weinstein, A., Williams, D. A., Wissel, S., Wood, M., Walker, R. C., Davies, F., Hardee, P. E., Junor, W., Ly, C., Aharonian, F., Akhperjanian, A. G., Anton, G., de Almeida, U. Barres, Bazer-Bachi, A. R., Becherini, Y., Behera, B., Bernlöhr, K., Bochow, A., Boisson, C., Bolmont, J., Borrel, V., Brucker, J., Brun, F., Brun, P., Bühler, R., Bulik, T., Büsching, I., Boutelier, T., Chadwick, P. M., Charbonnier, A., Chaves, R. C. G., Cheesebrough, A., Chounet, L-M., Clapson, A. C., Coignet, G., Dalton, M., Daniel, M. K., Davids, I. D., Degrange, B., Deil, C., Dickinson, H. J., Djannati-Ataï, A., Domainko, W., OʼC. Drury, L, Dubois, F., Dubus, G., Dyks, J., Dyrda, M., Egberts, K., Emmanoulopoulos, D., Espigat, P., Farnier, C., Feinstein, F., Fiasson, A., Förster, A, Fontaine, G., Füling, M., Gabici, S., Gallant, Y. A., Gérard, L, Gerbig, D., Giebels, B., Glicenstein, J. F., Glück, B., Goret, P., Göhring, D., Hauser, D., Hauser, M., Heinz, S., Heinzelmann, G., Henri, G., Hermann, G., Hinton, J. A, Hoffmann, A., Hofmann, W., Holleran, M., Hoppe, S., Horns, D., Jacholkowska, A., de Jager, O. C., Jahn, C., Jung, I., Katarzynski, K., Katz, U., Kaufmann, S., Kendziorra, E., Kerschhaggl, M., Khangulyan, D., Khélifi, B., Keogh, D., Kluzniak, W., Kneiske, T., Komin, Nu., Kosack, K., Lamanna, G., Lenain, J.-P., Lohse, T., Marandon, V., Martin, J. M., Martineau-Huynh, O., Marcowith, A., Maurin, D., L McComb, T. J., Medina, M. C., Moderski, R., Moulin, E., Naumann-Godo, M., de Naurois, M., Nedbal, D., Nekrassov, D., Nicholas, B., Niemiec, J., Nolan, S. J., Ohm, S., Olive, J.-F., de Oña Wilhelmi, E., Orford, K. J., Ostrowski, M., Panter, M., Arribas, M. Paz, Pedaletti, G., Pelletier, G., Petrucci, P.-O., Pita, S., Pühlhofer, G., Punch, M., Quirrenbach, A., Raubenheimer, B. C., Raue, M., Rayner, S. M., Renaud, M., Rieger, F., Ripken, J., Rob, L, Rosier-Lees, S., Rowell, G., Rudak, B., Rulten, C. B., Ruppel, J., Sahakian, V., Santangelo, A., Schlickeiser, R., Schöck, F. M., Schröder, R., Schwanke, U., Schwarzburg, S., Schwemmer, S., Shalchi, A, Sikora, M., Skilton, J. L, Sol, H., Spangler, D., Stawarz, L., Steenkamp, R., Stegmann, C., Stinzing, F., Superina, G., Szostek, A, Tam, P. H., Tavemet, J.-P., Terrier, R., Tibolla, O., Tluczykont, M., van Eldik, C., Vasileiadis, G., Venter, C., Venter, L, Vialle, J. P., Vincent, P., Vivier, M., Völk, H. J., Volpe, F., Wagner, S. J., Ward, M., Zdziarski, A. A., Zech, A., Anderhub, H., Antonelli, L. A., Antoranz, P., Backes, M., Baixeras, C., Balestra, S., Barrio, J. A., Bastieri, D., González, J. Becerra, Becker, J. K., Bednarek, W., Berger, K., Bernardini, E., Biland, A, Bock, R. K., Bonnoli, G., Bordas, P., Tridon, D. Borla, Bosch-Ramon, V., Bose, D., Braun, I., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Commichau, S., Contreras, J. L, Cortina, J., Costado, M. T., Covino, S., Curtef, V., Dazzi, F., De Angelis, A., De Cea del Pozo, E., Mendez, C. Delgado, De los Reyes, R., De Lotto, B., De Maria, M., De Sabata, F., Dominguez, A., Dorner, D., Doro, M., Elsaesser, D., Errando, M., Ferenc, D., Fernández, E., Firpo, R., Fonseca, M. V., Font, L., Galante, N., Garcia López, R. J., Garczarczyk, M., Gaug, M., Goebel, F., Hadasch, D., Hayashida, M., Herrero, A., Hildebrand, D., Höhne-Mönch, D., Hose, J., Hsu, C. C., Jogler, T., Kranich, D., Barbera, A. La, Laille, A., Leonardo, E., Lindfors, E., Lombardi, S., Longo, F., López, M, Lorenz, E., Majumdar, P., Maneva, G., Mankuzhiyil, N., Mannheim, K., Maraschi, L, Mariotti, M., Martinez, M., Mazin, D., Meucci, M., Miranda, J. M., Mirzoyan, R., Miyamoto, H., Moldón, J., Moles, M., Moralejo, A., Nieto, D., Nilsson, K., Ninkovic, J., Oya, I., Paoletti, R., Paredes, J. M., Pasanen, M., Pascoli, D., Pauss, F., Pegna, R. G., Perez-Torres, M. A., Persic, M., Peruzzo, L, Prada, F., Prandini, E., Puchades, N., Reichardt, I., Rhode, W., Ribó, M., Rico, J., Rissi, M., Robert, A., Rügamer, S., Saggion, A., Saito, T. Y., Salvati, M., Sanchez-Conde, M., Satalecka, K., Scalzotto, V., Scapin, V., Schweizer, T., Shayduk, M., Shore, S. N., Sidro, N., Sierpowska-Bartosik, A., Sillanpää, A., Sitarek, J., Sobczynska, D., Spanier, F., Stamerra, A., Stark, L S., Takalo, L, Tavecchio, F., Temnikov, P., Tescaro, D., Teshima, M., Torres, D. F., Turini, N., Vankov, H., Wagner, R. M., Zabalza, V., Zandanel, F., Zanin, R., and Zapatero, J.

Published
2009

48. Physics and astrophysics with a ground-based gamma-ray telescope of low energy threshold

Author

Fort, J. Albert i, Armada, A., Baixeras, C., Bartko, H., Bastieri, D., Bednarek, W., Bigongiari, C., Biland, A., Bisesi, E., Blanch, O., Bock, R.K., Bretz, T., Chilingarian, A., Ciprini, S., Commichau, S., Contreras, J.L., Cortina, J., Danielyan, V., Dazzi, F., De Angelis, A., De Lotto, B., Domingo, E., Dorner, D., Doro, M., Epler, O., Ferenc, D., Fernández, E., Firpo, R., Flix, J., Fonseca, M.V., Font, L., Galante, N., Garczarczyk, M., Gaug, M., Gebauer, J., Giannitrapani, R., Giller, M., Goebel, F., Hengstebeck, T., Jacon, P., de Jager, O.C., Kalekin, O., Kranich, D., Laille, A., Lenisa, T., Lindfors, E., Longo, F., López, M., López, J., Lorenz, E., Lucarelli, F., Mannheim, K., Mariotti, M., Martinez, M., Mase, K., Mazin, D., Merck, C., Merck, M., Meucci, M., Meyer, M., Mirzoyan, R., Mizobuchi, S., Moralejo, A., Oña-Wilhelmi, E., Orduña, R., Otte, N., Paneque, D., Paoletti, R., Pasanen, M., Pascoli, D., Pauss, F., Pavel, N., Pegna, R., Peruzzo, L., Piccioli, A., Pin, M., de los Reyes, R., Rico, J., Renker, D., Robert, A., Rossato, G., Saggion, A., Sánchez, A., Sartori, P., Scalzotto, V., Schweizer, T., Shayduk, M., Shinozaki, K., Sillanpää, A., Sobczynska, D., Stamerra, A., Stark, L., Takalo, L., Teshima, M., Tonello, N., Torres, A., Turini, N., Viertel, G., Vitale, V., Volkov, S., Wagner, R., Wibig, T., and Wittek, W.

Published
2005
Full Text
View/download PDF

50. Observation of Pulsed γ-Rays Above 25 GeV from the Crab Pulsar with MAGIC

Author

Aliu, E., Anderhub, H., Antonelli, L A., Antoranz, P., Backes, M., Baixeras, C., Barrio, J. A., Bartko, H., Bastieri, D., Becker, J. K., Bednarek, W., Berger, K., Bernardini, E., Bigongiari, C., Biland, A., Bock, R. K., Bonnoli, G., Bordas, P., Bosch-Ramon, V., Bretz, T., Britvitch, I., Camara, M., Carmona, E., Chilingarian, A., Commichau, S., Contreras, J. L., Cortina, J., Costado, M. T., Covino, S., Curtef, V., Dazzi, F., De Angelis, A., del Pozo, E. De Cea, Reyes, R. de los, De Lotto, B., De Maria, M., De Sabata, F., Mendez, C. Delgado, Dominguez, A., Dorner, D., Doro, M., Elsässer, D., Errando, M., Fagiolini, M., Ferenc, D., Fernandez, E., Firpo, R., Fonseca, M. V., Font, L, Galante, N., Garcia Lopez, R. J., Garczarczyk, M., Gaug, M., Goebel, F., Hadasch, D., Hayashida, M., Herrero, A., Höhne, D., Hose, J., Hsu, C. C., Huber, S., Jogler, T., Kranich, D., La Barbera, A., Laille, A., Leonardo, E., Lindfors, E., Lombardi, S., Longo, F., Lopez, M., Lorenz, E., Majumdar, P., Maneva, G., Mankuzhiyil, N., Mannheim, K., Maraschi, L., Mariotti, M., Martinez, M., Mazin, D., Meucci, M., Meyer, M., Miranda, J. M., Mirzoyan, R., Moles, M., Moralejo, A., Nieto, D., Nilsson, K., Ninkovic, J., Otte, N., Oya, I., Paoletti, R., Paredes, J. M., Pasanen, M., Pascoli, D., Pauss, F., Pegna, R. G., Perez-Torres, M. A., Persic, M., Peruzzo, L., Piccioli, A., Prada, F., Prandini, E., Puchades, N., Raymers, A., Rhode, W., Ribó, M., Rico, J., Rissi, M., Robert, J A., Rügamer, S., Saggion, A., Saito, T. Y., Salvati, M., SanchezConde, M., Sartori, P., Satalecka, K., Scalzotto, V., Scapin, V., Schweizer, T., Shayduk, M., Shinozaki, K., Shore, S. N., Sidro, N., Sierpowska-Bartosik, A., Sillanpää, A., Sobczynska, D., Spanier, F., Stamerra, A., Stark, L. S., Takalo, L., Tavecchio, F., Temnikov, P., Tescaro, D., Teshima, M., Tluczykont, M., Torres, D. F., Turini, N., Vankov, H., Venturini, A., Vitale, V., Wagner, R. M., Wittek, W., Zabalza, V., Zandanel, F., Zanin, R., Zapatero, J., de jager, O. C., and Wilheimi, E. de Ona

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results